Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 10;3(Suppl 1):e000455.
doi: 10.1136/esmoopen-2018-000455. eCollection 2018.

Immunotherapy for hepatocellular carcinoma: current status and future perspectives

Takuji Okusaka  1 , Masafumi Ikeda  2
Affiliations
Review

Immunotherapy for hepatocellular carcinoma: current status and future perspectives

Takuji Okusaka et al. ESMO Open. .

Abstract

The discovery of the immune checkpoint mechanism has contributed greatly to recent advances in cancer treatment. The anticytotoxic T lymphocyte-associated protein 4 antibody ipilimumab was first approved as a therapeutic drug for malignant melanoma in the USA in 2011; since then, antiprogrammed cell death 1 (PD-1) antibody and antiprogrammed death-ligand 1 (PD-L1) antibody have also been approved and clinically introduced and are indicated for the treatment of various cancers. Numerous clinical studies are now underway to evaluate the efficacy of immune checkpoint inhibitors for patients with many kinds of cancer, including hepatocellular carcinoma (HCC), and the outcomes of these trials are highly anticipated. Synergic effects of immune checkpoint inhibitors used in combination with molecular targeted agents or local therapy have also been suggested, resulting in expectations regarding the use of these drugs in combination with existing standard treatment methods for HCC. Thus, the treatment of HCC is now entering an age of significant innovation triggered by the clinical introduction of immune checkpoint inhibitors.

Keywords: CTLA-4; PD-1; PD-L1; hepatocellular carcinoma; immune checkpoint inhibitor.

PubMed Disclaimer

References

    1. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389:2492–502. 10.1016/S0140-6736(17)31046-2 - DOI - PMC - PubMed
    1. Sangro B, Park J-W, Cruz CMD. A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. J Clin Oncol 2016;34.
    1. Zhu AX, Finn RS, Cattan S. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. J Clin Oncol 2018;36(suppl 4S):abstr 209.
    1. Finn RS, Chan SL, Zhu AX, et al. Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240. J Clin Oncol 2017;35(15_suppl):TPS4143 10.1200/JCO.2017.35.15_suppl.TPS4143 - DOI
    1. Qin S, Finn RS, Kudo M, et al. A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma. J Clin Oncol 2018;36(15_suppl):TPS3110 10.1200/JCO.2018.36.15_suppl.TPS3110 - DOI